Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias W Beckmann

Showing results (521-530 of 799) with videos related to

Pageof 80
Sort By:
The Lancet. Oncology|November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trialSara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
Oncology Research and Treatment|March 1, 2018
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-StudyFabienne Schochter, Brigitte Rack, Marie Tzschaschel, et al.
JAMA Oncology|June 24, 2021
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical TrialThomas W P Friedl, Tanja Fehm, Volkmar Müller, et al.
Breast Care (Basel, Switzerland)|November 5, 2010
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)Matthias W Beckmann, Jens-Uwe Blohmer, Serban-Dan Costa, et al.
Breast Cancer Research and Treatment|May 5, 2018
BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patientsMarius Wunderle, Paul Gass, Lothar Häberle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2021
The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer AgentsPauline Dürr, Katja Schlichtig, Carolin Kelz, et al.
Oncotarget|November 5, 2017
Clinical validation of genetic variants associated with <i>in vitro</i> chemotherapy-related lymphoblastoid cell toxicityPeter A Fasching, Lothar Häberle, Brigitte Rack, et al.
Cancers|April 12, 2022
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer PatientsHanna Huebner, Lothar Häberle, Volkmar Müller, et al.
Breast Cancer Research and Treatment|March 13, 2013
Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasisChristian R Loehberg, Katrin Almstedt, Sebastian M Jud, et al.
Geburtshilfe Und Frauenheilkunde|December 23, 2017
Update Breast Cancer 2017 - Implementation of Novel TherapiesMichael P Lux, Wolfgang Janni, Andreas D Hartkopf, et al.
Pageof 80

Showing results (521-530 of 799) with videos related to

Sort By:
Pageof 80
The Lancet. Oncology|November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trialSara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
Oncology Research and Treatment|March 1, 2018
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-StudyFabienne Schochter, Brigitte Rack, Marie Tzschaschel, et al.
JAMA Oncology|June 24, 2021
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical TrialThomas W P Friedl, Tanja Fehm, Volkmar Müller, et al.
Breast Care (Basel, Switzerland)|November 5, 2010
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)Matthias W Beckmann, Jens-Uwe Blohmer, Serban-Dan Costa, et al.
Breast Cancer Research and Treatment|May 5, 2018
BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patientsMarius Wunderle, Paul Gass, Lothar Häberle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2021
The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer AgentsPauline Dürr, Katja Schlichtig, Carolin Kelz, et al.
Oncotarget|November 5, 2017
Clinical validation of genetic variants associated with <i>in vitro</i> chemotherapy-related lymphoblastoid cell toxicityPeter A Fasching, Lothar Häberle, Brigitte Rack, et al.
Cancers|April 12, 2022
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer PatientsHanna Huebner, Lothar Häberle, Volkmar Müller, et al.
Breast Cancer Research and Treatment|March 13, 2013
Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasisChristian R Loehberg, Katrin Almstedt, Sebastian M Jud, et al.
Geburtshilfe Und Frauenheilkunde|December 23, 2017
Update Breast Cancer 2017 - Implementation of Novel TherapiesMichael P Lux, Wolfgang Janni, Andreas D Hartkopf, et al.
Pageof 80